Jasper Therapeutics
Enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies.
Launch date
Employees
Market cap
$322m
Enterprise valuation
$217m (Public information from Sep 2024)
Share price
$23.91 JSPR
Redwood City California (HQ & founding location)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 4.4m | 1.4m |
| % growth | - | - | - | - | - | - | (68 %) |
| EBITDA | (9.8m) | (43.1m) | (64.1m) | (67.2m) | - | - | - |
| Profit | (31.7m) | (30.6m) | (37.7m) | (64.5m) | (61.6m) | (76.5m) | (99.5m) |
| % profit margin | - | - | - | - | - | (1739 %) | (7069 %) |
| EV / revenue | - | - | - | - | - | 42.5x | 234.0x |
| EV / EBITDA | -12.8x | -7.0x | 0.3x | -1.3x | - | - | - |
| R&D budget | 15.9m | 25.4m | 34.6m | 51.8m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Series A | ||
$100m Valuation: $490m -50.0x EV/LTM EBITDA | SPAC IPO | ||
$100m Valuation: $490m -50.0x EV/LTM EBITDA | SPAC Private Placement | ||
* | N/A | $90.0m | Post IPO Equity |
* | $50.0m | Post IPO Equity | |
| Total Funding | $100m | ||
Related Content
Recent News about Jasper Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.